SCHEMBL19706061

SCHEMBL19706061

Cc1nc(NC(=O)N(c2nc(-c3cccc(C(F)(F)F)c3)ccc2N)C2CCCC2)sc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.41
▸ RAB9A P51151 4/20 0.39
▸ POLB P06746 2/20 0.39
▸ ALDH1A1 P00352 3/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ CRHR1 P34998 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ NPC1 O15118 2/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ PIK3CD O00329 1/20 0.37
▸ PIK3CA P42336 1/20 0.37
▸ PIK3CG P48736 1/20 0.37
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ PKM P14618 1/20 0.35
▸ CSNK2A2 P19784 1/20 0.35
▸ CSNK2B P67870 1/20 0.35
▸ CSNK2A1 P68400 1/20 0.35
▸ CSNK2A3 Q8NEV1 1/20 0.35
▸ UCHL1 P09936 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19365862 0.90 KDM1A (0.40) KDM1AALDH1A1MAPK1CRHR1SMN1; SMN2
SCHEMBL19365801 0.89 RAB9A (0.38) RAB9APOLBALDH1A1MAPK1CRHR1
SCHEMBL19670283 0.87 RAB9A (0.39) RAB9AALDH1A1MAPK1SMN1; SMN2NPC1
SCHEMBL19365514 0.85 ALDH1A1 (0.37) RAB9AALDH1A1MAPK1SMN1; SMN2NPC1
SCHEMBL19365609 0.84 TRPV1 (0.46) KDM1AMAPK1PIK3CDPIK3CAPIK3CG
SCHEMBL19365814 0.84 NPC1 (0.41) RAB9APOLBALDH1A1MAPK1SMN1; SMN2
SCHEMBL19706034 0.83 ALDH1A1 (0.39) KDM1ARAB9AALDH1A1MAPK1SMN1; SMN2
SCHEMBL19365572 0.82 BLM (0.45) POLBALDH1A1MAPK1SMN1; SMN2MEN1
SCHEMBL19365329 0.82 RAB9A (0.39) RAB9AALDH1A1MAPK1SMN1; SMN2NPC1
SCHEMBL19670378 0.82 RAB9A (0.41) RAB9AALDH1A1MAPK1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 KDM1A 859/4885RAB9A 1471/4885POLB 961/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 KDM1A 859/4885RAB9A 1471/4885POLB 961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback